SCHEMBL2747980

SCHEMBL2747980

COc1cc2ncnc(Nc3ccc4c(C(=O)Nc5cccc(Cl)c5)cccc4c3)c2cc1OC

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 6/20 0.68
▸ KDM4E B2RXH2 2/20 0.68
▸ MAPT P10636 2/20 0.68
▸ MAPK1 P28482 2/20 0.68
▸ MAPK14 Q16539 2/20 0.68
▸ MEN1 O00255 1/20 0.68
▸ GMNN O75496 1/20 0.68
▸ ALDH1A1 P00352 1/20 0.68
▸ ABL1 P00519 1/20 0.68
▸ LMNA P02545 1/20 0.68
▸ RAF1 P04049 1/20 0.68
▸ TP53 P04637 1/20 0.68
▸ CYP1A2 P05177 1/20 0.68
▸ GLA P06280 1/20 0.68
▸ CYP3A4 P08684 1/20 0.68
▸ FBP1 P09467 1/20 0.68
▸ CYP2D6 P10635 1/20 0.68
▸ SRC P12931 1/20 0.68
▸ HPGD P15428 1/20 0.68
▸ ALOX15 P16050 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2747131 0.91 KDR (0.74) EGFRMAPK14KDR
SCHEMBL2747187 0.88 KDR (0.71) EGFRMAPK14KDR
SCHEMBL2746962 0.84 KDR (0.62) EGFRMAPK14SRCKDRLCK
SCHEMBL2746015 0.84 KDR (0.62) EGFRMAPK14SRCKDRLCK
SCHEMBL31067722 0.83 EGFR (0.84) EGFRKDM4EMAPTMAPK1MAPK14
Tyrphostin Ag-1478 SCHEMBL31079458 0.83 EGFR (1.00) EGFRKDM4EMAPTMAPK1MAPK14
Tyrphostin Ag-1478 SCHEMBL29483198 0.83 EGFR (1.00) EGFRKDM4EMAPTMAPK1MAPK14
Tyrphostin Ag-1478 SCHEMBL93838 0.83 EGFR (1.00) EGFRKDM4EMAPTMAPK1MAPK14
Tyrphostin Ag-1478 SCHEMBL29350062 0.83 EGFR (1.00) EGFRKDM4EMAPTMAPK1MAPK14
SCHEMBL4549037 0.82 KDR (0.69) EGFRMAPK14ABL1KDRLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 — — US disclosed
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 — — US disclosed
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 — — US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 — — US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 — — US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 — — US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 — — US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 — — US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 — — US disclosed
US-20060241115-A1 Compounds and methods of use AMGEN INC. 2006-10-26 — — US disclosed
EP-1713484-A2 COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2006-10-25 — — EP disclosed
WO-2005070891-A2 COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2005-08-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241115-A1 Compounds and methods of use HGF, HGFAC, MET EGFR 129/4885KDM4E 4131/4885MAPT 2653/4885
US-20090176774-A1 Compounds and methods of use HGF, HGFAC, MET EGFR 129/4885KDM4E 4131/4885MAPT 2653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback